Month: January 2024

WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a proprietary drug-delivery technology to improve patient access, safety, and convenience, today announced the closing of a bridge financing with a syndicate of investors. Following the closing, the investors exercised a purchase option to acquire all of the outstanding common stock of the Company not already held by the investors to take the Company private. The financing and option exercise follows a robust effort by the Company, led by a Special Committee of the Company’s Board of Directors, to explore strategic alternatives to maximize shareholder value. Comera will continue to focus on licensing the Company’s proprietary SQore™ technology platform to strategic...

Chairman of the Board Heng Fai Ambrose Chan Adds 672,173 Shares to Increase Investment in Company NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) — DSS, Inc. (NYSE American: DSS, “Company”), a multinational company operating across four distinct market sectors, announced today a significant investment by its Chairman of the Board, Heng Fai Ambrose Chan. In a strategic move to bolster shareholder confidence and underscore his commitment to the company’s growth. Chairman Chan acquired an additional 672,173 shares of DS, Inc. in an open market transaction on December 28, 2023.  Frank Heuszel, CEO of DSS, Inc., expressed his enthusiasm for Mr. Chan’s increased stake, viewing it as a strong vote of confidence in the company’s strategic direction and future potential. Heuszel said, “Chairman Chan’s decision to augment...

Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A First-in-Class Compound Designed to Treat Metastatic Disease BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (“TransCode” or the “Company”) (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced publication of an open letter to shareholders outlining the Company’s progress in 2023 and objectives in 2024. The text of the letter is below. Dear Shareholders, As we begin the new year, we reflect on the challenges faced by the biotech sector over the past two years. Despite those challenges, we have the pleasure to report on TransCode’s progress and resilience and solicit your continued support. Our...

IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) — Mobix Labs, Inc. (Nasdaq: MOBX), a fabless semiconductor company developing disruptive next-generation connectivity technologies for 5G infrastructure, satellite communications, and defense industries, today announced it has been awarded a 15-month contract to supply electromagnetic interference (EMI) Filtered Connectors as part of the U.S. Army’s M-1 Abrams Tank program. Under the terms of the agreement, Mobix Labs will supply filtered connectors to an undisclosed Honeywell subcontractor until June 2025. Financial details were not disclosed. “This is a key design win and validation of our successful acquisition of EMI Solutions as we continue to gain further access into the large and important military vertical,” said Fabian Battaglia, CEO of Mobix Labs. “We are honored to be a...

Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from the companies’ fibrosis research collaboration. The compound represents a novel approach to treating fibrotic diseases with compelling early data suggesting the potential to reverse disease-related fibrotic processes, including immuno-mesenchymal dysfunction. “Since initiating our research collaboration with Bayer in 2020, we have worked diligently to apply the power of the Recursion OS to identify and advance potential candidates in challenging areas of disease...

EDISON, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) — Zerify Inc. (OTC PINK: ZRFY), a pioneer in cybersecurity specializing in secure video conferencing and endpoint security, is delighted to present its revenue projection for 2024. Additionally, the company offers the latest updates on recently disclosed transactions and deals. Mark L. Kay, CEO of Zerify expressed his enthusiasm for the company’s trajectory, highlighting, “We are extremely optimistic about both our company’s future and that of our shareholders. Our Zerify Meet & Defender technologies represent the most groundbreaking innovations in the video conferencing market over the past two decades. We firmly believe that no other company in this industry can match the competitive advantages we possess.” “That’s why in 2024 Zerify is projecting $3.9M...

ZyVersa is developing two proprietary product platforms targeting renal and inflammatory diseases.Cholesterol Efflux MediatorTM VAR 200, designed to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, leading to chronic kidney disease and its progression. Inflammasome ASC Inhibitor IC 100, designed to inhibit multiple inflammasome pathways to attenuate initiation and perpetuation of damaging inflammation pathogenic in numerous inflammatory diseases.WESTON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Noble Capital Markets has initiated company-sponsored equity...